How are energy investors positioned?
On Friday, JMP Securities analyst Daniel Stauder increased the price target for LeMaitre Vascular (NASDAQ:LMAT) to $113 from $100, while maintaining a Market Outperform rating on the stock. According to InvestingPro data, five analysts have recently revised their earnings estimates upward for the upcoming period, with price targets ranging from $85 to $117. While the company shows strong momentum, trading at $99.91, InvestingPro’s Fair Value analysis suggests the stock is currently overvalued. Stauder’s decision came after evaluating LeMaitre’s performance in the final quarter of fiscal 2024, which showcased a 14% organic sales growth, a 30% improvement in earnings per share (EPS), and a 220 basis point expansion in operating margin year-over-year.
LeMaitre reported revenue slightly below the company’s quarterly guidance, with $55.7 million compared to the projected $55.9 million at the midpoint. However, the EPS of $0.49 met expectations. The company maintains impressive financial metrics, with InvestingPro showing a robust gross profit margin of 68.3% and strong returns on equity of 13%. Looking ahead, LeMaitre’s initial guidance for 2025 suggests that the company expects to continue its solid performance. The revenue guidance midpoint is $239 million, closely aligning with the $240 million consensus, while the projected full-year EPS represents a 16% year-over-year growth, surpassing analyst expectations at $2.24 compared to the consensus of $2.16.
Stauder highlighted the company’s consistent financial results and the sustained momentum throughout 2024, both in revenue and profit margins. LeMaitre has been actively expanding its sales team, extending its geographic presence, securing regulatory approvals, and focusing on driving its core product categories in targeted markets. These efforts have contributed to disciplined operating leverage and improved cash flow generation, which has been further bolstered by a recent convertible note offering that added $168 million to the company’s finances.
The analyst expressed confidence in LeMaitre’s potential for further improvement, citing the company’s steady financial performance and strategic initiatives that have positioned it for continued success. The upgraded price target reflects this optimism and the anticipation of LeMaitre’s ongoing growth trajectory.
In other recent news, LeMaitre Vascular reported its fourth-quarter 2024 financial results, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.49, exceeding the forecast of $0.46, and reported revenue of $55.7 million, slightly above the expected $55.49 million. The company’s performance was bolstered by a 14% year-over-year sales growth and a 26% increase in operating income. Despite these positive results, LeMaitre Vascular’s stock experienced a decline amid broader market volatility and investor concerns about future growth. The company is progressing with its expansion plans in China and Europe, aiming to enhance its market presence. Additionally, LeMaitre Vascular anticipates a 10% organic sales growth and a gross margin of 69.7% for the full year 2025. Wells Fargo (NYSE:WFC) Securities recently initiated coverage on the company, highlighting the interest from financial analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.